Icometrix

Icometrix provides artificial intelligence-powered software solutions for the analysis of brain MRI and CT scans. The company was founded in 2011 by Dirk Loeckx and Wim Van Hecke as a spin-off from the universities and university hospitals of Antwerp and Leuven in Belgium. The founders recognized the valuable information within brain scans and the difficulty for clinicians to extract it efficiently, leading them to develop AI to bridge this gap.

The company's core product is the icobrain software portfolio, which has received both CE-marking and FDA clearance. This cloud-based platform extracts clinically meaningful data from brain scans to assist in the diagnosis, monitoring, and treatment of neurological disorders such as multiple sclerosis (MS), Alzheimer's disease, dementia, traumatic brain injury, stroke, and epilepsy. The software quantifies brain structures and abnormalities, providing objective metrics that help clinicians track disease progression and treatment response. For instance, 'icobrain ms' helps monitor MS by tracking lesion and brain volume changes, while 'icobrain dm' assists in diagnosing dementia by identifying patterns in brain volume loss. In November 2024, the FDA cleared 'icobrain aria,' the first AI software for detecting and grading Amyloid-Related Imaging Abnormalities (ARIA), a potential side effect of some Alzheimer's therapies.

Icometrix serves hospitals, imaging centers, radiologists, and neurologists. Its business model involves providing its software as a service, which is integrated into clinical workflows. The company also collaborates with pharmaceutical companies on clinical trials and real-world evidence studies. Icometrix has established partnerships with major medical technology companies like Siemens Healthineers and Philips to integrate its AI solutions into their platforms. In September 2025, GE HealthCare announced its agreement to acquire Icometrix, aiming to integrate the icobrain platform with its MRI systems to meet the growing demand for personalized neurological treatment planning.

Over its history, Icometrix has raised a total of $20.2 million in funding over 10 rounds, with a significant Series A round of $18 million in 2019 led by Forestay Capital, Optum Ventures, and Capricorn Venture Partners. During the COVID-19 pandemic in 2020, the company launched icolung to analyze chest CT scans and also introduced icompanion, a digital platform and app for MS patients to monitor their health. The company is headquartered in Leuven, Belgium, with a U.S. presence in Boston.

Keywords: medical imaging AI, neurological disorders, brain MRI analysis, CT scan quantification, icobrain, multiple sclerosis monitoring, Alzheimer's diagnosis, dementia analysis, traumatic brain injury, stroke assessment, epilepsy imaging, radiology software, digital health, neuroimaging, lesion tracking, brain atrophy measurement, clinical decision support, GE HealthCare, FDA cleared AI, personalized medicine, medical software, health technology